Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)

16 Apr 2013

Abstract excerpt

This study: (i) investigated the in vitro cytotoxicity and mode of action of lurbinectedin (PM01183) and Zalypsis® (PM00104) compared with trabectedin in cell lines deficient in specific mechanisms of repair, (ii) evaluated their in vivo antitumor activity against a series of murine tumors and human xenografts. The antiproliferative activity, the DNA damage and the cell cycle perturbations induced by the three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Microbial Natural Products and Biosynthesis
Share to Synthesis and biological activity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23588839
DOI: 10.1002/ijc.28213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)PMID 23588839Read ↗

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant CellsSemantic proximity Read ↗

Role of homologous recombination in trabectedin-induced DNA damage.Semantic proximity Read ↗

Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell linesSemantic proximity Read ↗

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinSemantic proximity Read ↗

Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcriptionSemantic proximity Read ↗

The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and ChemotherapySemantic proximity Read ↗

Evolution of Nitrogen-Based Alkylating Anticancer AgentsSemantic proximity Read ↗

The role of DNA repair in nitrogen mustard drug resistanceSemantic proximity Read ↗

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabineSemantic proximity Read ↗

Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.Semantic proximity Read ↗

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase IISemantic proximity Read ↗

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.